No Data
No Data
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Marlborough, Massachusetts–(Newsfile Corp. – July 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Phio Pharmaceuticals Corp -Deal Afforded Triton Opportunity to Purchase up to 18.8% of Co’s Common Stock
Express News | Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds, Which Afforded Triton Opportunity To Purchase Up To 18.8% Of Co.'s Common Stock
Express News | Phio Pharmaceuticals Corp - Terminates Share Purchase Agreement With Triton
Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology
No Data